Table 1 Table Quality of Life Measures and Outcomes in Randomized Controlled Trials for Psoriasis Treatments

"Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial" (2005) 40

Efalizumab 1 mg/kg/wk (n = 529) or placebo (n = 264) for 12 weeks

1. SF-36

2. DLQI

3. PSA

4. VAS for itching

5. PGPA

QOL, measured using all QOL measures, was significantly higher among the Efalizumab group as compared with the placebo group (p < 0.001)

"Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial" (2005) [41]

Etanercept 50 mg twice weekly (n = 194) Placebo (n = 193), etanercept 50 mg per week (n = 196) during the initial 12-week, double-blind period.

1.DLQI

2.SF-36

3. PGPA

DLQI total score improved by 65–70% in etanercept group compared with 6% in placebo group (P < 0.0001). Significant improvement in etanercept group as measured by other SF-36 and PGPA

"Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate" (2005) [42]

Alefacept (Amevive^®)

1. PASI

2. DLQI

The QOL effects of alefacept in patients who were not candidates for conventional systemic psoriasis therapies or phototherapy were similar to those reported previously for the overall alefacept-treated population in the phase III studies (p = 0.001).

"Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial" (2005) [43]

Intravenous infusions of 3 or 5 mg kg(-1) of infliximab or placebo

DLQI

Infliximab induction therapy resulted in a substantial improvement in HRQOL. At week 10, patients in the infliximab 3- and 5-mg kg(-1) groups showed a median percentage improvement in DLQI scores of 84.0% and 91.0%, respectively, compared with 0% in the placebo group (P < 0.001)

"The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions" (2003) [44]

Clobetasol propionate foam (clobetasol foam) 0.05%

PGA

Clobestasol propionate foam 0.05% had greater improvement in QoL as compared to other topical therapies reported by patients.

"Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporine" (2001) [45]

Cyclosporin (Neoral^®) (n = 255)

1. DLQI

2. PASI

Intermittent short courses of cyclosporin significantly improved the QoL of the patients and decreases the extent and severity of disease and itch

"The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial" (2004) [46]

Combination therapy with topical vitamin D analogue calcipotriol (50 microg g(-1)) and corticosteroid betamethasone dipropionate (0.5 mg g(-1)) vs. calcipotriol monotherapy

1. PDI

2. EuroQoL 5D

3. VAS

Once-daily application of the combination product was found to be superior to calcipotriol twice daily terms of QoL

"The effect of treatment on quality of life in psoriasis patients" (2005) [47]

Treatment with short contact dithranol treatment, UVB phototherapy or inpatient dithranol

1. Dutch short form of the SIP

2. PDI

Comparable improvement in HRQoL with short contact dithranol treatment and UVB phototherapy, inpatients experienced a more impaired HRQoL and showed no significant improvement in HRQoL directly following treatment

"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis" (2003) [48]

Methotrexate (n= 44; initial dose, 15 mg per week) or cyclosporine (n= 44; initial dose, 3 mg per kilogram of body weight per day)

1. PASI

2. PGA

The difference in the QOL for both the treatment arms was statistically insignificant

"Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis" (2000) [49]

Combination of UVB (311 nm) and tazarotene vs. UVB (311 nm) plus calcipotriol or vice versa

PASI

No significant differences in QoL of patients in both the regimens

"A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis" (1998) [50]

Calcipotriol ointment (50 micrograms/g) twice daily or Dithrocream (short-contact dithranol) 0.1–2%

1. PDI

2. SIP

Significant improvement in patients' QoL as assessed by the PDI and the SIP were seen in both treatment groups, with greater improvement in calcipotriol group